Sun Pharma Q2 Net Profit Falls 36% on Exceptional Charges; Revenue Rises 12%
Sun Pharmaceutical Industries reported a 36 percent year-on-year decline in consolidated net profit to approximately Rs 1,989 crore for Q2 FY27, mainly due to exceptional charges including a Rs 923 crore US litigation settlement and Rs 346 crore acquisition-related costs for its proposed Organon deal. Revenue rose nearly 12 percent to about Rs 16,199 crore, driven by growth in domestic formulations and emerging markets. Excluding exceptional items, adjusted profit showed a slight increase. The Organon acquisition is expected to close in Q4 FY27.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 38/100.
Outlets measured: news18, economictimes, economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (42–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 30 Oct, 09:02 am. Other outlets followed.